Drugs / flt3 ligand
flt3 ligand
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02955550 | Jan 2017 → Jul 2018 | plasma cell myeloma | Celularity Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT02781467 | Jul 2016 → Dec 2017 | acute myeloid leukemia | Celularity Incorporated | Terminated | No outcome recorded |
| Phase 1 | NCT00003431 | Jun 1998 → May 2001 | colorectal cancer, metastatic malignant neoplasm | Duke University | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00019396 | Feb 1998 → Mar 2007 | melanoma, renal cell carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00006223 | Jul 2000 → Jan 2007 | leukemia | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00020540 Background | Mar 2001 → ? | cutaneous melanoma, kidney cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00005787 Background | Sep 1999 → Jan 2002 | lymphoma, neutropenia | Northwestern University | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00006225 Background | Nov 1999 → Jan 2004 | breast cancer, leukemia, myelodysplastic/myeloproliferative disease, plasma cell neoplasm | Northwestern University | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | flt3 ligand | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00006223 ↗ |
| Known as | Flt3L | “Patients receive Flt3 ligand (Flt3L) subcutaneously (SQ) alone on days 1-14.” NCT00019396 ↗ |
| Known as | PNK-007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02955550 ↗ |
| Modality | Protein / enzyme biologic | “recombinant flt3 ligand” NCT00003431 ↗ |
| Route | Subcutaneous | “Patients receive flt3 ligand subcutaneously for 14 days” NCT00003431 ↗ |